Table 2 Differences in demographic, clinical and laboratory parameters and pharmacological treatment between SoC and Intensive therapy group at end of intervention
Parameter | End of treatment | ||
|---|---|---|---|
SoC Group (n = 169) | Intervention group (n = 199) | p** | |
Systolic blood pressure (mmHg) | 135.1 (15.2) | 127.3 (8.7) | 0.004 |
Diastolic blood pressure (mmHg) | 78.8 (8.8) | 78.1 (5.6) | 0.110 |
BP < 130/80 mmHg (%) | 132 (74.2) | 163 (84.5) | 0.045 |
Laboratory tests | |||
eGFR EPI-CKD (mL/min) | 60.7 (22.9) | 60.4 (22.5) | 0.920 |
Albuminuria (mg/day) | 90.2 (38–160) | 54 (11–180) | 0.179 |
Albuminuria < 30 mg/day (%) | 18 (13.0) | 62 (37.6) | 0.047 |
Fasting plasma glucose (mg/dL) | 153.6 (44.8) | 147.4 (39.4) | 0.199 |
HbA1c (%) | 7.4 (1.1) | 6.9 (0.6) | 0.009 |
HbA1c < 7% (%) | 88 (52.1) | 129 (64.8) | 0.133 |
Total cholesterol (mg/dL) | 190.9 (33) | 173 (28.9) | 0.015 |
Total cholesterol < 175 mg/dL (%) | 55 (32.5) | 106 (53.2) | 0.054 |
LDL cholesterol (mg/dL) | 122.3 (29.8) | 100.5 (26.5) | < 0.001 |
LDL < 100 mg/dL (%) | 34 (20.1) | 106 (53.2) | 0.001 |
Triglycerides (mg/dL), median (IQR) | 122 (90–171) | 145 (120–169) | 0.794 |
Therapy | |||
Anti-hypertensive drugs, median (IQR) | 1 (1–3) | 2 (1–3) | < 0.001 |
ACEi/ARBs, No. (%) | |||
ACEi | 104 (61.8) | 7 (3.4) | |
ARBs | 56 (33.1) | 5 (2.3) | |
ACE + ARBs | 3 (1.8) | 187 (94.3) | |
None | 6 (3.6) | – | < 0.001 |
Diuretics, No. (%) | 84 (49.7) | 113 (56.8) | 0.864 |
Calcium channel Blockers, No. (%) | 59 (34.9) | 79 (39.7) | 0.687 |
Beta-blockers, No. (%) | 30 (17.8) | 38 (19.1) | 0.961 |
Alpha-blockers, No. (%) | 6 (3.6) | 10 (4.8) | 0.574 |
Diabetes therapy, No. (%) | 0.843 | ||
Diet | 5 (2.9) | 5 (2.5) | |
Insulin | 57 (33.7) | 73 (36.7) | |
Oral anti-hyperglycemics | 77 (45.6) | 88 (44.2) | |
Combined therapy | 16 (9.5) | 25 (12.6) | |
Missing | 14 (8.3) | 8 (4) | |
Use of statins, No. (%) | 84 (49.7) | 110 (55.3) | 0.991 |
Use of antiplatelets, No. (%) | 104 (61.6) | 148 (74.4) | 0.905 |